Menu

News

ERS Genomics Licenses CRISPR Gene Editing Technology to DefiniGEN to Develop Human Cell Models to Support the Preclinical Development of Therapeutics

ERS Genomics Licenses CRISPR Gene Editing Technology to DefiniGEN to Develop Human Cell Models to Support the Preclinical Development of Therapeutics

4th January 2019

DUBLIN, Ireland, and CAMBRIDGE, UK, November 1, 2018 – ERS Genomics Limited and DefiniGEN Ltd announced today a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. DefiniGEN will combine their best-in-class iPSC (induced Pluripotent Stem Cell) differentiation platform with CRISPR/Cas9 technology to generate a range of innovative preclinical […]

DefiniGEN at the World Preclinical Congress 2018

DefiniGEN at the World Preclinical Congress 2018

30th November 2018

DefiniGEN will be attending the World Preclinical Congress Europe on November 27-30th 2018 in Lisbon. DefiniGEN invites all WPC 2018 attendees wanting to discover more about how its range of human cell products and services can be used in disease modelling and drug discovery applications to visit booth #18. Contact us to arrange a meeting […]